Travere Therapeutics, Inc.
About Travere Therapeutics, Inc.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $490.7M
- Net income
- -$25.5M
- Total assets
- $605.2M
- Market cap
- $4.3B
- Gross margin
- 97.9%
- Operating margin
- -12.8%
- Net margin
- -5.2%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $490.7M
- Cost of revenue
- $10.3M
- Gross profit
- $480.4M
- Operating expenses
- $543.2M
- Operating income
- -$62.8M
- Income tax
- $988.0K
- Net income
- -$25.5M
- EPS (basic)
- $-0.29
- EPS (diluted)
- $-0.29
Balance sheet
- Total assets
- $605.2M
- Current assets
- $437.6M
- Total liabilities
- $490.4M
- Current liabilities
- $159.9M
- Shareholders’ equity
- $114.8M
Cash flow
- Operating cash flow
- $37.8M
- Investing cash flow
- $27.9M
- Financing cash flow
- -$33.5M
- Net cash flow
- $34.5M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $4.3B
- EPS (diluted)
- $-0.29
- Shares outstanding
- 90.5M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jul 23, 2003
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $25.5M in FY2025.
- Revenue grew 147% from FY2020 to FY2025.
- Gross margin of 97.9%, net margin -5.2%.
- Trading near its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Travere Therapeutics, Inc..
Write a review
News about Travere Therapeutics, Inc.
News & sentiment via Polygon.io
